Hemoglobin, hematocrit and heart failure: the SGLT2 inhibitor connection

19 May 2025 (16:00 - 16:45)

Organised by:

Video

Abstract

Sign in to view the resources

Slides

About the speaker

Mr Diogo Ferreira

Santa Maria Hospital - CHULN, Lisbon (Portugal)

4 More presentations in this session

Presentation thumbnail

Effects of glucagon like peptide 1 receptor agonist initiation in patients with heart failure and reduced ejection fraction and implantable cardiac devices

Doctor P. Marques (Porto, PT)

Abstract Slides Video

Presentation thumbnail

Real-world burden of heart failure with reduced ejection fraction and dapagliflozin use at 2 years after approval in 9 countries from Central Eastern Europe and Baltic Area: EVOLUTION-HF CEE-BA study

Professor I. Gruev (Sofia, BG)

Abstract Slides Video

Presentation thumbnail

Safety and efficacy of early initiation of mineralocorticoid receptor antagonists in patients with worsening heart failure: a meta-analysis of randomized controlled trials

Doctor R. Laborante (Stockholm, SE)

Abstract Slides Video

Presentation thumbnail

Socioeconomic disparities in guideline directed medical therapy for HFrEF: a population-based cohort study using electronic health records (the Netherlands)

Ms J. van Eijk (Utrecht, NL)

Abstract Slides Video

Access the full session

Session thumbnail

Digitoxin and other therapeutic strategic advances

The Event

Event poster

Heart Failure 2025

19 May 2025 16:00 CET

You may be interested in

Congress Presentation

Effects of SGLT-2 inhibitors on erythropoiesis and the associated cardio-renal benefits in patients with chronic heart failure

Congress Presentation

Hematological outcomes of SGLT-2 inhibitors in heart failure patients: a systematic review and meta-analysis

Congress Session

Further Insights into SGLT2i treatment for heart failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources